Biologics Development: A Regulatory Overview 3rd EditionBarnett Educational ServicesMarch 1, 2004 SKU: BNT1870213 |
| Biologics Development: A Regulatory Overview 3rd Edition (2004) is the only text on Biologics Development and Regulation in the Post-CBER/CDER Consolidation Era! Completely revised and updated to address the transfer of therapeutic biological products to CDER, this all-new edition provides the most comprehensive and up-to-date analysis of the FDA's emerging processes for regulating and approving biological products. Written by CDER and CBER officials and industry experts, Biologics Development: A Regulatory Overview offers an expansive examination of the FDA's regulation of biologic products, from preclinical testing to post-marketing regulatory requirements, and from user fees to electronic submissions. Better yet, this new text provides the first detailed look inside the re-invented FDA that will regulate and approve today's biological products Please note: The delivery of this report requires Adobe 6 or higher, and the ability to install right management plugin for Adobe. |
Related Markets
Biopharmaceuticals Reports
- Research Report on Chinese Bio-pharmaceutical Industry, 2012
- Regulatory Intelligence on Biologics Recalls – Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes
- Biologics Market in Brazil
- Global Biosimilars Market Forecast to 2015
- Biosimilars: Current Situation & Future Prospects, Worldwide
